What Is AICAR / Acadesine?
AICAR is a synthetic nucleoside used in metabolic and cardiovascular research. It is also called acadesine and AICA riboside. After entering cells, it can be phosphorylated to AICAR monophosphate, commonly called ZMP, which resembles adenosine monophosphate and can activate AMP-activated protein kinase.
That explanation is often compressed into “AICAR tricks the body into thinking it exercised”. The reality is more complicated. AMPK is an important energy-sensing enzyme, but exercise coordinates mechanical work, blood flow, neural signalling, hormones and adaptations across many tissues. AICAR has AMPK-dependent and AMPK-independent effects, including changes in adenosine metabolism.
The most famous study reported a 44% increase in running endurance after four weeks in sedentary mice. Human development followed a different path: acadesine was studied mainly as an adenosine-regulating medicine intended to reduce ischaemia and reperfusion injury around coronary-artery bypass surgery. The largest trial enrolled 3,080 people and stopped early for futility.
Is AICAR a peptide?
No. AICAR is frequently grouped with peptides by research-chemical websites, but chemically it is a ribonucleoside. It contains a ribose sugar joined to 5-aminoimidazole-4-carboxamide.
The naming creates additional confusion:
| Name | Usually means |
|---|---|
| AICAR | Often the cell-permeable riboside used experimentally; context is essential |
| Acadesine | International non-proprietary name for AICA riboside |
| AICA riboside | The unphosphorylated nucleoside that can enter cells |
| ZMP or AICAR monophosphate | The intracellular phosphorylated ribonucleotide that mimics some AMP signals |
| AICA ribonucleotide | A natural intermediate in de-novo purine synthesis, usually referring to the monophosphate form |
Calling every form “AICAR” can make an extracellular research chemical sound identical to a normal intracellular metabolite. They are connected, but location and phosphorylation state change what the molecule can do.
What is AMPK?
AMP-activated protein kinase, or AMPK, is a cellular energy sensor. When energy demand rises, ATP is consumed and relative levels of AMP or ADP increase. AMPK integrates these signals with upstream kinases and other inputs.
Once activated, AMPK tends to support ATP-generating processes and restrain selected energy-consuming ones. Depending on tissue and context, this can include:
- increasing glucose uptake
- increasing fatty-acid oxidation
- reducing lipid and protein synthesis
- influencing mitochondrial adaptation
- modifying autophagy and cell-growth pathways
This is a regulatory network rather than an on-off “fat-burning switch”. AMPK activation during exercise occurs alongside muscle contraction, calcium signalling, catecholamines, oxygen demand and repeated recovery. Pharmacologically raising one signal cannot recreate that complete state.
How does AICAR activate AMPK?
The riboside enters cells through nucleoside transporters and is phosphorylated by adenosine kinase to form ZMP. ZMP can bind regulatory sites associated with AMPK and promote activation, partly by helping upstream phosphorylation and resisting dephosphorylation.
ZMP is only a partial biochemical imitation of AMP. It can accumulate to concentrations far above ordinary signalling levels and affect other AMP-sensitive enzymes. These include enzymes involved in glycogen, fructose and purine metabolism.
AICAR can also change extracellular and intracellular adenosine handling. That mattered to its cardiovascular development because adenosine can dilate blood vessels and protect tissue during ischaemic stress.
It is therefore inaccurate to describe every AICAR result as proof that AMPK caused the effect. Genetic knockout, inhibitor and pathway experiments have identified both AMPK-dependent and AMPK-independent actions.
Is AICAR the same as AMP?
No. AMP is adenosine monophosphate, one of the cell's ordinary adenine nucleotides. ZMP resembles AMP sufficiently to influence some AMP-sensitive systems but differs chemically and does not reproduce every interaction.
The administered riboside is also not ZMP at the moment of exposure. It must enter a cell and be phosphorylated. Transporter abundance and adenosine-kinase activity therefore influence response. Different tissues and experimental models can generate different intracellular exposure from the same extracellular concentration.
How was AICAR developed?
AICAR was known in nucleotide biochemistry long before the “exercise pill” headlines. Its medical development initially focused on controlling adenosine during ischaemia.
| Period | Development |
|---|---|
| Mid-20th century | AICA riboside and its role in purine metabolism characterised |
| 1980s and 1990s | Acadesine developed as an adenosine-regulating agent for myocardial ischaemia and cardiac surgery |
| 1990s | AICAR became a widely used laboratory method for activating AMPK in intact cells |
| 2007 | A small human physiology experiment reported increased skeletal-muscle glucose uptake |
| 2008 | Sedentary mice showed a 44% endurance increase after four weeks, popularising the “exercise mimetic” description |
| 2009 onward | AICAR prohibited in sport by WADA |
| 2010 | RED-CABG stopped early for futility |
| 2012 | Full RED-CABG results showed no reduction in the primary clinical outcome |
| Current position | Widely used research reagent, not an approved performance, obesity or longevity medicine |
The chronology matters. People were exposed to acadesine in cardiac trials before AMPK became its best-known public identity. Those trials cannot be presented as evidence that chronic AMPK activation improves fitness.
Why was acadesine studied during heart surgery?
Coronary-artery bypass grafting temporarily changes blood flow and can expose heart tissue to ischaemia followed by reperfusion. Reperfusion restores oxygen but can also trigger oxidative stress, inflammation and cellular injury.
Acadesine was intended to increase adenosine availability preferentially in metabolically stressed tissue. Adenosine can reduce inflammatory-cell activation, alter vascular tone and limit aspects of ischaemia-reperfusion injury. This was described as adenosine regulation rather than continuous systemic adenosine delivery.
Early cardiac-surgery studies and pooled analyses generated encouraging signals, including possible reductions in perioperative myocardial infarction. A large confirmatory trial was needed because smaller studies, subgroup analyses and composite outcomes can overestimate benefit.
What did the RED-CABG trial find?
RED-CABG was a multicentre, randomised, double-blind, placebo-controlled Phase III trial in higher-risk patients undergoing on-pump coronary-artery bypass surgery. It enrolled 3,080 participants with an average age of 67; 61% had diabetes and 48% had experienced a previous myocardial infarction.
The primary outcome combined all-cause death, nonfatal stroke or need for mechanical left-ventricular support within 28 days. It occurred in:
- 5.1% of the acadesine group
- 5.0% of the placebo group
- p=0.94
The individual components were similarly close. All-cause mortality was 1.9% versus 1.8%, nonfatal stroke 1.7% versus 1.7%, and need for mechanical support 2.3% versus 2.3%.
The trial stopped early after a futility assessment. Futility does not mean the medicine was proven to have no biological effect. It means the accumulating results made success on the planned clinical question sufficiently unlikely that continuing was not justified.
RED-CABG is the strongest human efficacy evidence for acadesine, and it was negative. Earlier encouraging cardiac signals should be interpreted in light of this larger controlled result.
What did the mouse endurance study actually show?
The 2008 Cell paper tested metabolic pathways associated with endurance adaptation. Sedentary mice received AICAR for four weeks. The study reported changes in oxidative genes and a 44% increase in treadmill running endurance without exercise training.
This was a meaningful animal experiment. The design linked AMPK-related signalling with PPAR-delta and muscle oxidative metabolism. It did not show that human beings gain the same endurance, that the effect is safe, or that systemic pharmacology reproduces the broader health effects of training.
Several translation gaps are important:
- mice metabolise drugs differently from humans
- treadmill endpoints in mice are influenced by motivation and experimental protocol
- four weeks does not establish long-term organ safety
- systemic AMPK activation affects more than skeletal muscle
- exercise improves tendons, bones, coordination, cardiovascular capacity and mental health through mechanisms beyond AMPK
The study supports the term “exercise mimetic” only in a narrow experimental sense. It does not establish exercise replacement.
Has AICAR improved muscle glucose uptake in humans?
A small physiological study examined AICA riboside and glucose uptake in healthy men. Research of this type can demonstrate that human skeletal muscle responds metabolically during controlled exposure.
An acute change in glucose uptake is not evidence of durable diabetes treatment, fat loss or improved exercise performance. It does not show an improvement in HbA1c, diabetic complications, cardiovascular outcomes or body composition.
AMPK also interacts with insulin-dependent and contraction-dependent glucose transport. A laboratory clamp or infusion experiment asks a mechanistic question under controlled conditions, not whether self-administered AICAR safely improves metabolic health.
Does AICAR burn fat or cause weight loss?
AICAR can increase fatty-acid oxidation and alter lipid metabolism in cells and animal models. Those biochemical effects are often converted into a consumer claim that it “burns fat”.
Human fat loss requires sustained change in energy balance and body composition. No adequate randomised human obesity programme has shown that AICAR produces clinically meaningful, durable weight loss with acceptable safety.
AMPK can also inhibit lipolysis in certain adipocyte contexts, illustrating why pathway slogans can mislead. Tissue, timing and metabolic state determine whether a measured change favours storage, mobilisation or oxidation.
Is AICAR an anti-ageing compound?
AMPK participates in nutrient sensing, mitochondrial biology and autophagy, all of which are studied in ageing. Recent mouse experiments have examined whether chronic AICAR preserves muscle or function in older animals.
Animal improvement does not establish longer life, reduced disability or safe treatment in older people. Chronic activation could affect cardiac tissue, liver, immune cells and cell growth differently from intermittent exercise.
There is no approved anti-ageing indication and no human longevity trial showing that AICAR extends healthy lifespan.
Has AICAR been studied in cancer?
AICAR can inhibit proliferation or alter survival pathways in cell and animal cancer models. Some effects involve AMPK, while others reflect purine metabolism, nucleotide stress or AMPK-independent signalling.
Cancer cells differ enormously in genotype and metabolic dependence. AMPK can restrain growth under some conditions but also help cells survive energy stress under others. A laboratory antiproliferative result cannot support general anticancer use.
Acadesine has been explored in haematological research, including chronic lymphocytic leukaemia and acute lymphoblastic leukaemia. It has not become a broadly approved cancer medicine. Interactions with normal immune and blood-forming cells remain relevant.
Why is AICAR prohibited in sport?
The World Anti-Doping Agency classifies AICAR under S4.4.1 metabolic modulators as an AMPK activator. It is prohibited at all times, meaning both in and out of competition.
The rule addresses performance manipulation rather than medical approval. A substance can be prohibited because of performance potential, health risk or conflict with the spirit of sport even if robust athlete efficacy data are unavailable.
AICAR has been on the prohibited list since 2009. WADA-supported research has developed methods to distinguish administered AICAR exposure from the body's endogenous purine metabolite background, including measurement of AICAR ribotide in red blood cells and population thresholds.
Supplements or research products marketed without the word AICAR may still present anti-doping risk through contamination, mislabelling or synonyms such as acadesine and AICA riboside. Athletes remain responsible under strict-liability rules.
What is known about safety?
Clinical acadesine exposure occurred mainly in monitored hospital settings, often around surgery. That record provides more human information than exists for many research compounds, but it does not establish the safety of chronic performance or body-composition use.
Potential concerns follow from its broad metabolic actions:
- changes in blood glucose and substrate use
- effects on uric-acid and purine metabolism
- vascular and cardiac effects related to adenosine
- liver or kidney exposure
- interactions with cell growth and blood-cell function
- unknown consequences of sustained AMPK activation across tissues
RED-CABG excluded people with chronic kidney disease, gout and elevated liver enzymes. Those exclusions are a reminder that trial safety cannot be generalised to populations deliberately kept out of the study.
An experimental performance setting also differs from a short hospital infusion. Product identity, repeated exposure, concurrent stimulants or metabolic agents and absence of laboratory monitoring create uncertainties not answered by the surgical trials.
How is AICAR synthesised and characterised?
AICAR is a small nucleoside rather than a chain assembled by standard peptide synthesis. Chemical manufacture must construct the substituted imidazole carboxamide and attach the ribofuranose with the correct stereochemistry.
Analytical identity can use nuclear magnetic resonance, high-resolution mass spectrometry, chromatography and comparison with a qualified reference standard. Relevant impurities may include starting materials, stereoisomers, degradation products, residual solvents and related purine compounds.
The phosphate status must be explicit. A product labelled AICAR may claim to contain the riboside, while ZMP is the phosphorylated nucleotide. Mass and chromatography should distinguish them.
For injectable clinical material, sterility, bacterial endotoxin, particles, concentration, pH, osmolality, container compatibility and stability are separate requirements. A research-reagent assay does not establish pharmaceutical suitability.
Is AICAR approved?
AICAR is not an FDA-, MHRA- or EMA-approved medicine for athletic performance, exercise replacement, obesity, diabetes, cancer or ageing. Acadesine's late-stage cardiac programme did not demonstrate benefit in RED-CABG.
The existence of human trials does not equal marketing authorisation. Nor does its natural relationship to purine metabolism make an externally supplied product a supplement.
How strong is the evidence overall?
| Question | Best available evidence | Defensible conclusion |
|---|---|---|
| Can AICAR activate AMPK-related signalling? | Extensive cell, animal and human mechanistic research | Yes, after cellular conversion to ZMP, with important non-AMPK effects |
| Does it increase endurance? | Four-week sedentary-mouse experiment | Yes in that model; comparable human performance benefit is unproven |
| Does it replace exercise? | No adequate whole-body human comparison | No |
| Does acadesine protect high-risk CABG patients? | 3,080-person randomised Phase III trial | No benefit on the primary clinical outcome |
| Does it cause human fat loss? | No adequate obesity programme | Not established |
| Is it an anti-ageing treatment? | Laboratory and animal research | Not established in humans |
| Is it permitted in tested sport? | WADA Prohibited List | No, it is prohibited at all times |
The evidence is substantial enough to understand the biochemistry and to reject simplistic claims. It is not a clinical evidence base for performance, weight loss or longevity use.
What claims are not established?
AICAR has not been shown to give people the equivalent of a workout, improve race performance safely, build muscle, reduce body fat, reverse diabetes or extend life. It has not supplied an evidence-based consumer “cycle”.
Evidence for exercise training should not be attributed to an AMPK activator, and results from acute hospital infusion should not be transferred to repeated research-chemical use.
Frequently asked questions
What does AICAR stand for?
It commonly refers to 5-aminoimidazole-4-carboxamide riboside. The same acronym is also used for the intracellular ribonucleotide, so context matters.
Is AICAR the same as acadesine?
Yes, when AICAR means AICA riboside. Acadesine is its international non-proprietary drug name.
Is AICAR a peptide?
No. It is a purine-related nucleoside.
What is ZMP?
ZMP is the monophosphorylated form made inside cells. It mimics some AMP signals and can activate AMPK.
Does AICAR activate AMPK directly?
The administered riboside must first enter cells and be phosphorylated to ZMP. Its effects are not exclusively mediated by AMPK.
Why is AICAR called an exercise mimetic?
A 2008 study found increased oxidative gene expression and 44% greater treadmill endurance in sedentary mice after four weeks.
Does AICAR improve human endurance?
No adequate controlled human performance trial has established this.
Did acadesine work in heart surgery?
The 3,080-person RED-CABG trial found no reduction in its primary outcome and stopped early for futility.
Does AICAR cause weight loss?
No robust human obesity trial has established clinically meaningful or durable weight loss.
Is AICAR FDA approved?
No. It is not approved for performance, obesity, diabetes, ageing or cardiac-surgery protection.
Is AICAR banned in sport?
Yes. WADA prohibits it at all times as a metabolic modulator and AMPK activator.
Is AICAR naturally present in the body?
The phosphorylated ribonucleotide is an intermediate in de-novo purine synthesis. External acadesine can raise cellular ZMP far beyond ordinary signalling conditions.
Is AICAR the same as GW501516?
No. AICAR is converted to an AMP mimetic; GW501516 is a PPAR-delta agonist. Both appear in anti-doping discussions but are chemically and pharmacologically different.
Can AICAR replace training?
No. Exercise produces mechanical, cardiovascular, neural and psychological adaptations that AMPK activation alone cannot reproduce.
Are research-grade AICAR products equivalent to clinical acadesine?
No equivalence has been established for identity, purity, formulation, sterility, exposure or safety.
What would convincing future evidence require?
A performance or metabolic programme would require a defined pharmaceutical product, human pharmacokinetics, tissue-response markers, careful organ monitoring and randomised outcomes that matter to participants. Exercise studies would need to compare AICAR, structured training and their combination rather than infer equivalence from one molecular pathway.
Any future indication would also have to explain why systemic AMPK and purine manipulation offers an acceptable benefit-risk balance compared with established treatments. The failed Phase III cardiac result shows that plausible metabolic protection is not enough.
The bottom line
AICAR is an important research tool and a genuine human investigational drug with a long history. It helped scientists probe cellular energy sensing and produced a striking endurance result in mice.
The popular story omits the distinction between riboside and ZMP, its non-AMPK actions and the gap between mouse running and human health. It also overlooks the largest clinical test: acadesine did not improve the primary outcome in 3,080 high-risk CABG patients.
AICAR should therefore be understood as an unapproved metabolic modulator, not exercise in a vial. Its WADA prohibition reflects its performance-manipulation potential, not proof that it safely improves human performance.
Research notice
This guide is educational. It does not provide dosing, administration, preparation, cycling, stacking or purchasing guidance.
Sources
Research reviewed through October 2026.